TORONTO, April 5, 2006 (PRIMEZONE) -- Biogenerics Limited (Pink Sheets:BIGN) announced today the location of its new head office, which will be relocated to 1520 Rice Road, Suite 200, Tyler, Texas, 75703. Not only is the Tyler head office an indicator of Biogenerics growing presence in the oil and gas industry, it also a reflection of the company's growth strategy which focuses on the employment of its strategic partners proprietary technology, such as Hydroslotter Corporation's enhanced oil recovery techniques in existing wells.
The state of Texas currently produces more than three times the natural gas than any other state and its continued energy production remains crucial to the success of the U.S. government's domestic energy mandate. Accordingly, Biogenerics move to Tyler will place the company in a prime position to increase oil and gas production in state of Texas as well as a platform to expand into other surrounding states with the goal of facilitating the U.S. government's domestic energy directive.
About Biogenerics Limited:
Biogenerics is a diversified investment venture capital firm focused on exploiting and distributing domestic oil and gas reserves. Biogenerics has oil and gas assets acquired from Rubicon Petroleum. The company also has joint venture activities with Tyche Energy and Hydroslotter Corporation.
About Hydroslotter Corporation:
Hydroslotter Corporation's proprietary technology deemed "hydroslotting" increases oil and gas production and extends commercial productivity of oil and gas by 300% to 600%. Hydroslotter's technology is cost effective and for the inexpensive cost of the actual re-work on potential shut-in wells, the return on investment is high.
Forward-Looking Statements:
A number of statements contained in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including timely development, and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions and the ability to secure additional sources of financing. The actual results of Biogenerics Limited may achieve could differ materially from any forward-looking statements due to such risks and uncertainties, including but not limited to, the fact that no assurance can be given that any proposed acquisitions will be consummated at all.